•] Shares PRELUDE THERAPEUTICS INCORPORATED COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENTUnderwriting Agreement • January 4th, 2021 • Prelude Therapeutics Inc • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • March 15th, 2023 • Prelude Therapeutics Inc • Pharmaceutical preparations • New York
INDEMNITY AGREEMENTIndemnity Agreement • September 4th, 2020 • Prelude Therapeutics Inc • Pharmaceutical preparations • Delaware
This Indemnity Agreement, dated as of ____________________ ____, 2020 is made by and between Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and _________________________, a director, officer or key employee of the Company or one of the Company’s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 4th, 2021 • Prelude Therapeutics Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of [ ], 2020 by and between Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 15th, 2024 • Prelude Therapeutics Inc • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 11, 2023, by and among Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 15th, 2024 • Prelude Therapeutics Inc • Pharmaceutical preparations • Delaware
This Executive Employment Agreement (the “Agreement”), made between Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and Bryant Lim (“Executive” and, collectively with the Company, the “Parties”), is entered into as of January 30, 2023.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 17th, 2022 • Prelude Therapeutics Inc • Pharmaceutical preparations • Delaware
This Executive Employment Agreement (the “Agreement”), made between Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and Laurent Chardonnet (“Executive” and, collectively with the Company, the “Parties”), is entered into as of 11/5/2021 | 5:16 PM EDT.
4,496,744 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) PRE-FUNDED WARRANTS TO PURCHASE 12,895,256 SHARES OF COMMON STOCK PRELUDE THERAPEUTICS INCORPORATED UNDERWRITING AGREEMENTUnderwriting Agreement • May 19th, 2023 • Prelude Therapeutics Inc • Pharmaceutical preparations • New York
SECOND AMENDED AND RESTATED ENTREPRENEUR CLIENT LICENSE AGREEMENTEntrepreneur Client License Agreement • November 4th, 2020 • Prelude Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED ENTREPRENEUR CLIENT LICENSE AGREEMENT (“License Agreement”), made as of the Effective Date between Licensee, and Delaware Innovation Space, Inc., a Delaware charitable non-profit nonstock corporation (“DISI”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • January 4th, 2021 • Prelude Therapeutics Inc • Pharmaceutical preparations • Delaware
This Executive Employment Agreement (the “Agreement”), made between Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and Christopher Pierce (“Executive” and, collectively with the Company, the “Parties”), is entered into as of December 19, 2020 (the “Effective Date”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • August 26th, 2020 • Prelude Therapeutics Inc • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of August 21, 2020 (the “Effective Date”), by and among Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and each holder of the Company’s Preferred Stock (as defined below) listed on Schedule A (with all such Persons, together with any subsequent transferees who become parties hereto as “Investors” pursuant to the terms hereof, the “Investors”).
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 15th, 2024 • Prelude Therapeutics Inc • Pharmaceutical preparations • New York
This Amended and Restated Registration Rights Agreement (this “Agreement”) is made as of December 11, 2023, by and between Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICY DISCLOSED. SINGLE-TENANT TRIPLE NET LEASESingle-Tenant Triple Net Lease • March 17th, 2022 • Prelude Therapeutics Inc • Pharmaceutical preparations
This Single-Tenant Triple Net Lease (this “Lease”) is made and entered into as of September 13, 2021 (the “Effective Date”), by and between CRISP PARTNERS LLC, a Delaware limited liability company (“Landlord”), and PRELUDE THERAPEUTICS INCORPORATED, a Delaware corporation (“Tenant”).
PRELUDE THERAPEUTICS INCORPORATED CONSULTING AGREEMENTConsulting Agreement • April 10th, 2024 • Prelude Therapeutics Inc • Pharmaceutical preparations
This Consulting Agreement (this “Agreement”) is entered into April 8th, 2024 (the “Effective Date”) between Prelude Therapeutics Incorporated, a Delaware corporation with its principal place of business at 175 Innovation Boulevard, Wilmington, Delaware 19805 USA (“Company”) and Laurent Chardonnet (“Consultant”). Company desires to retain Consultant to perform certain consulting activities as described below, and Consultant desires to serve as a consultant to Company and perform such activities under the terms of this Agreement.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 10th, 2022 • Prelude Therapeutics Inc • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”), made between Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and Jane Huang (“Executive” and, collectively with the Company, the “Parties”), is entered into as of January 21, 2022 (the “Effective Date”).
SEPARATION AGREEMENT AND GENERAL RELEASESeparation Agreement • April 10th, 2024 • Prelude Therapeutics Inc • Pharmaceutical preparations • Delaware
This Separation Agreement and General Release (“Agreement”) is between Prelude Therapeutics Incorporated (“Company”) and Laurent Chardonnet (“Employee”).
FIRST AMENDMENT TO SINGLE-TENANT TRIPLE NET LEASESingle-Tenant Triple Net Lease • March 17th, 2022 • Prelude Therapeutics Inc • Pharmaceutical preparations
This FIRST AMENDMENT TO SINGLE-TENANT TRIPLE NET LEASE (the “First Amendment”) is made as of _11/15/2021_, by and between CRISP PARTNERS LLC, a Delaware limited liability company (“Landlord”) and PRELUDE THERAPEUTICS INCORPORATED, a Delaware corporation (“Tenant”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • January 4th, 2021 • Prelude Therapeutics Inc • Pharmaceutical preparations • Delaware
This Executive Employment Agreement (the “Agreement”), made between Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and Krishna Vaddi (“Executive” and, collectively with the Company, the “Parties”), is entered into as of December 30, 2020 (the “Effective Date”).
